

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

CLAIM AMENDMENTS

Claims 1-38. (Canceled)

39. (Currently Amended) A compound of the formula:



wherein n is 1 to 15;

Y is a phenylalanyl radical having a phenyl ring, an amine end, ~~and a carboxyl end,~~
and a $-CH_2CH<$ group attached to the phenyl ring at the $-CH_2$ and the amine end and the
carboxyl end attached to the $CH<$, the phenyl ring having one or more substituents selected
from the group consisting of hydroxyl, carboxyl, formyl, carboxyalkyl, carboxyalkyloxy,
dicarboxyalkyl, dicarboxyalkyloxy, dicarboxyhaloalkyl, dicarboxyhaloalkyloxy, and
phosphonoalkyl, phosphonohaloalkyl, wherein the alkyl portion of the substituents of the
phenyl ring may be unsubstituted or substituted with a substituent selected from the group
consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, and alkoxy, ~~and keto;~~

W is a moiety attached to the nitrogen of Y and is selected from the group consisting
of alkylcarbonyl, oxalyl, alkylaminooxalyl, arylaminooxalyl, arylalkylaminooxalyl,
alkoxyoxalyl, carboxyalkyl carbonyl, heterocyclyl carbonyl, heterocyclylalkyl carbonyl,
arylalkyl heterocyclylalkyl carbonyl, aryloxycarbonyl, and arylalkoxycarbonyl, wherein the
aryl and alkyl portions of ~~the substituents~~ W may be unsubstituted or substituted with a
substituent selected from the group consisting of halo, hydroxy, ~~carboxyl, amino,~~ aminoalkyl,
alkyl, and alkoxy; and the heterocyclyl portion of W contains at least 4 hetero atoms selected
from the group consisting of O, N, and S;

AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and

Z is arylalkylamino or aryl heterocyclyl C_1-C_6 alkylamino wherein an aryl group,
which may be substituted or unsubstituted, is linked to a heterocyclyl group; wherein aryl is a
carbocyclic aryl;

or a salt thereof;

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

with the proviso that Z is not arylalkylamino when W is oxalyl or acetyl and the phenyl ring of phenylalanyl contains a hydroxyl, malonyl difluoromethyl, malonyloxy, carboxyalkyloxy, phosphonodifluoromethyl, or phosphonomethyl substituent on the phenyl ring at a position para to the ~~CH₂CH~~ group ~~-CH₂CH<~~ group of phenylalanyl and the ortho and meta positions are unsubstituted and the proviso that Z is not arylalkylamino when W is arylalkoxycarbonyl and the substituent on the phenyl ring of Y is phosphonomethyl.

40. (Currently Amended) A compound of the formula: W-Y-(AA)_n-Z wherein n is 1 to 15;

Y is a phenylalanyl radical having a phenyl ring, an amine end, ~~and a carboxyl end,~~ and a -CH₂CH< group attached to the phenyl ring at the -CH₂ and the amine end and the carboxyl end attached to the CH<, the phenyl ring having one or more substituents selected from the group consisting of hydroxyl, carboxyl, formyl, carboxy C₁-C₆ alkyl, carboxy C₁-C₆ alkyloxy, dicarboxy C₁-C₆ alkyl, dicarboxy C₁-C₆ alkyloxy, dicarboxyhalo C₁-C₆ alkyl, dicarboxyhalo C₁-C₆ alkyloxy, and phosphono C₁-C₆ alkyl, phosphonohalo C₁-C₆ alkyl, wherein the alkyl portion of the substituents of the phenyl ring may be unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, C₁-C₆ alkyl, and C₁-C₆ alkoxy, ~~and keto~~;

W is a moiety attached to the nitrogen of Y and is selected from the group consisting of C₁-C₆ alkylcarbonyl, oxalyl, C₁-C₆ alkylaminooxalyl, arylaminooxalyl, aryl C₁-C₆ alkylaminooxalyl, C₁-C₆ alkoxyoxalyl, carboxy C₁-C₆ alkyl carbonyl, heterocyclyl carbonyl, heterocyclyl C₁-C₆ alkyl carbonyl, aryl C₁-C₆ alkyl heterocyclyl C₁-C₆ alkyl carbonyl, aryloxy carbonyl, and aryl C₁-C₆ alkoxy carbonyl, wherein the aryl and alkyl portions of ~~the substituents~~ W may be unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, ~~carboxyl, amino~~, amino C₁-C₆ alkyl, C₁-C₆ alkyl, and C₁-C₆ alkoxy; and the heterocyclyl portion of W contains at least 4 hetero atoms selected from the group consisting of O, N, and S;

AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and

Z is aryl C₁-C₆ alkylamino or arylheterocyclyl C₁-C₆ alkylamino wherein an aryl group is linked to a heterocyclyl group; wherein aryl is a carbocyclic aryl group;

or a salt thereof;

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

with the proviso that Z is not aryl C₁-C₆ alkylamino when W is oxalyl or acetyl and the phenyl ring of phenylalanyl contains a hydroxyl, dicarboxyhaloalkyl, dicarboxyalkoxy, carboxyalkoxy, phosphonoalkyl, or phosphonohaloalkyl substituent of the phenyl ring at a position para to the CH₂CH-group ~~CH₂CH< group of phenylalanyl~~ and the ortho and meta positions are unsubstituted and the proviso that Z is not arylalkylamino when W is aryl methoxycarbonyl when the substituent on the phenyl ring of Y is phosphonomethyl.

41. (Currently Amended) A compound of the formula:

W-Y-(AA)_n-Z wherein n is 1 to 15:


W is a moiety attached to the nitrogen of Y and is selected from the group consisting of C₁-C₆ alkylcarbonyl, oxalyl, C₁-C₆ alkylaminooxalyl, arylaminooxalyl, aryl C₁-C₆ alkylaminooxalyl, C₁-C₆ alkoxyoxalyl, carboxy C₁-C₆ alkyl carbonyl, heterocyclyl carbonyl, heterocyclyl C₁-C₆ alkyl carbonyl, aryl C₁-C₆ alkyl heterocyclyl C₁-C₆ alkyl carbonyl, aryloxy carbonyl, and aryl C₁-C₆ alkoxy carbonyl, wherein the aryl and alkyl portions of W may be unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C₁-C₆ alkyl, C₁-C₆ alkyl, and C₁-C₆ alkoxy; and the heterocyclyl portion of W contains at least 4 hetero atoms selected from the group consisting of O, N, and S;

AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and

Z is aryl C₁-C₆ alkylamino or arylheterocyclyl C₁-C₆ alkylamino wherein an aryl group is linked to a heterocyclyl group; wherein aryl is a carbocyclic aryl group;

or a salt thereof;


The compound of claim 40; wherein Y is of the formula XI:




(XI)

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150


wherein D has the formula XII, XIII, or XIV:



(XII)



(XIII)



(XIV)

wherein R₃ and R₄ may be the same or different and are selected from the group consisting of hydrogen, C₁-C₆ alkyl, aryl, aryl C₁-C₆ alkyl, C₁-C₆ alkaryl, and heteroaryl; and R₅ and R₆ may be the same or different and are selected from the group consisting of hydrogen, halo, hydroxy, amino, and C₁-C₆ alkoxy; and

E is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylcarbonyl, carboxyl, and C₁-C₆ alkylcarbonyl C₁-C₆ alkyl;

with the proviso that Z is not aryl C₁-C₆ alkylamino when W is oxalyl or acetyl and D is hydroxyl, dicarboxyhaloalkyl, dicarboxyalkoxy, carboxyalkoxy, alkoxy-carbonylalkyl, phosphonoalkyl, or phosphonohaloalkyl and E is hydrogen.

42. (Previously Presented) The compound of claim 41, wherein D is of formula XII.

43. (Previously Presented) The compound of claim 41, wherein D is of formula XIII.

44. (Previously Presented) The compound of claim 41, wherein D is of formula XIV.

45. (Previously Presented) The compound of claim 42, wherein E is hydrogen.

46. (Previously Presented) The compound of claim 42, wherein E is carboxyl.

47. (Currently Amended) The compound of claim 42, wherein R₃, R₄, R₅, and R₆ are hydrogen.

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150


48. (Previously Presented) The compound of claim 44, wherein R_3 and R_4 are hydrogen.

49. (Currently Amended) The compound of claim 39, wherein W is selected from the group consisting of C_1 - C_6 alkylcarbonyl, oxalyl, C_1 - C_6 alkylaminooxalyl, arylaminooxalyl, aryl C_1 - C_6 alkylaminooxalyl, C_1 - C_6 alkoxyoxalyl, carboxy C_1 - C_6 alkyl carbonyl, heterocyclyl carbonyl, heterocyclyl C_1 - C_6 alkyl carbonyl, aryl C_1 - C_6 alkyl heterocyclyl C_1 - C_6 alkyl carbonyl, aryloxy carbonyl, and aryl C_1 - C_6 alkoxy carbonyl, wherein the aryl and alkyl portions of the substituents W may be unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C_1 - C_6 alkyl, C_1 - C_6 alkyl, and C_1 - C_6 alkoxy; and the heterocyclyl portion of W contains at least 4 hetero atoms selected from the group consisting of O, N, and S.

50-66. (Canceled)

67. (Previously Presented) The compound of claim 40, wherein Z is aryl C_1 - C_6 alkylamino.

68. (Previously Presented) The compound of claim 67, wherein the aryl portion of Z has the formula:




wherein Q_1 is hydrogen or a substituent selected from the group consisting of hydroxyl, halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino, and C_1 - C_6 acylamino.

69-72. (Canceled)

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

73. (Currently Amended) The compound of claim 39, wherein the aryl heterocyclyl portion of Z has the formula:



wherein Q_2 is hydrogen or a substituent selected from the group consisting of hydroxyl, halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino, and C_1 - C_6 acylamino, and F and G are independently selected from the group consisting of C, N, O, and S; with the proviso that F and G are not simultaneously C.

74-77. (Canceled)

78. (Previously Presented) The compound of claim 39, wherein said amino acid is selected from the group consisting of glycine, alanine, valine, norvaline, leucine, iso-leucine, norleucine, α -amino n-decanoic acid, serine, homoserine, threonine, methionine, cysteine, S-acetylaminomethyl-cysteine, proline, trans-3- and trans-4-hydroxyproline, phenylalanine, tyrosine, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β -phenylserine β -hydroxyphenylalanine, phenylglycine, α -naphthylalanine, cyclohexylalanine, cyclohexylglycine, tryptophan, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aspartic acid, asparagine, aminomalonic acid, aminomalonic acid monoamide, glutamic acid, glutamine, histidine, arginine, lysine, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine, α -aminocyclopentane carboxylic acid, α -aminocyclohexane carboxylic acid, α -aminocycloheptane carboxylic acid, α -(2-amino-2-norbornane)-carboxylic acid, α,γ -diaminobutyric acid, α,β -diaminopropionic acid, homophenylalanine, and α -tert-butylglycine.


79-84. (Canceled)

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

85. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 39.

86-115. (Canceled)

116. (Currently Amended) A compound of the formula:



wherein n is 0 to 15;

Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, a -CH₂CH< group attached to the phenyl ring at the CH₂ and the amine end and the carboxyl end are attached to the CH<, the phenyl ring having the following substituent or a combination of substituents: (i) dicarboxy C₁-C₆ alkyl, (ii) hydroxyl and carboxy C₁-C₆ alkyl, (iii) carboxyl and carboxy C₁-C₆ alkyl, or (iv) ~~dicarboxyhalo C₁-C₆ alkyl~~, or dicarboxyhalo C₁-C₆ alkyloxy; or an ester of (i), (ii), (iii), or (iv); wherein the alkyl portion of the substituents of the phenyl ring may be unsubstituted or substituted with a substituent selected from the group consisting of ~~halo~~, hydroxy, carboxyl, amino, aminoalkyl, C₁-C₆ alkyl, and C₁-C₆ alkoxy, ~~and keto~~;

W is a moiety attached to the nitrogen of Y and is selected from the group consisting of C₁-C₆ alkylcarbonyl, oxalyl, C₁-C₆ alkylaminooxalyl, arylaminooxalyl, aryl C₁-C₆ alkylaminooxalyl, C₁-C₆ alkoxyoxalyl, carboxy C₁-C₆ alkyl carbonyl, heterocyclyl carbonyl, heterocyclyl C₁-C₆ alkyl carbonyl, aryl C₁-C₆ alkyl heterocyclyl C₁-C₆ alkyl carbonyl, aryloxy carbonyl, and aryl C₁-C₆ alkoxy carbonyl, wherein the aryl and alkyl portions of the substituents W may be unsubstituted or substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, amino C₁-C₆ alkyl, C₁-C₆ alkyl, and C₁-C₆ alkoxy; and the heterocyclyl portion of W contains at least 4 hetero atoms selected from the group consisting of O, N, and S;

AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and


Z is aryl C₁-C₆ alkylamino or arylheterocyclyl C₁-C₆ alkylamino wherein an aryl group is linked to a heterocyclyl group; wherein aryl is a carbocyclic aryl;
or a salt thereof.

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

117. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 116.

118-119. (Canceled)

120. (Currently Amended) The compound of claim 39, which is of the formula:



121. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 120.

122. (Previously Presented) A method for inhibiting an SH2 domain of a protein from binding with a phosphoprotein comprising contacting the SH2 domain with the compound of claim 120.

123. (Currently Amended) A method of ~~preventing or treating a disease, state, or condition, in a mammal comprising administering~~ inhibiting proliferation of cells in a patient that exhibit erb-2 signalling comprising contacting the cells with the compound of claim 120.

124. (Currently Amended) A method of inhibiting MAP kinase activity in a mammal comprising administering to the mammal in need thereof the compound of claim 120.

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

125. (Canceled)

126. (Previously Presented) The compound of claim 116, wherein n is 1-3.

127. (Previously Presented) The compound of claim 116, wherein Z is naphthylpropylamino.

128. (Previously Presented) The compound of claim 116, wherein the phenyl ring of Y includes a malonyl group.

129. (Previously Presented) The compound of claim 116, wherein the phenyl ring of Y includes a carboxymethyl group and a hydroxyl group.

130. (Previously Presented) The compound of claim 116, wherein said amino acid is selected from the group consisting of glycine, alanine, leucine, isoleucine, norleucine, cyclohexylalanine, 4-aminocyclohexylglycine, 4-acetylamino-cyclohexylglycine, aspartic acid, asparagine, glutamic acid, and glutamine.

131-132. (Canceled)

133. (Currently Amended) A method for treating breast cancer in a patient comprising administering to the patient an effective amount of the compound of claim 120.

134-135. (Canceled)

136. (Currently Amended) A method of enhancing the therapeutic effect of a cancer treatment rendered to a mammal that has been afflicted with a cancer, comprising administering to the mammal the compound of claim 120 in conjunction with the treatment, wherein the treatment comprises chemotherapy, radiation therapy, or biological therapy.

137-139. (Canceled)

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

140. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 40.

141. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 41.

142. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 42.

143. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 43.

144. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 44.

145. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 49.

146. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 68.

147. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 73.

148. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 78.

149. (New) A method for inhibiting an SH2 domain of a protein from binding with a phosphoprotein comprising contacting the SH2 domain with the compound of claim 39.

150. (New) A method for inhibiting an SH2 domain of a protein from binding with a phosphoprotein comprising contacting the SH2 domain with the compound of claim 40.

151. (New) A method for inhibiting an SH2 domain of a protein from binding with a phosphoprotein comprising contacting the SH2 domain with the compound of claim 41.

In re Appln. of Burke, Jr., et al.
Application No. 09/937,150

152. (New) A method of inhibiting proliferation of cells in a patient that exhibit erb-2 signaling comprising contacting the cells with a compound of claim 39.

153. (New) A method of inhibiting proliferation of cells in a patient that exhibit erb-2 signaling comprising contacting the cells with a compound of claim 40.

154. (New) A method of inhibiting proliferation of cells in a patient that exhibit erb-2 signaling comprising contacting the cells with a compound of claim 41.

155. (New) A method for inhibiting the growth of human breast cancer cells comprising contacting the cells with a compound of claim 39.

156. (New) A method for inhibiting the growth of human breast cancer cells comprising contacting the cells with a compound of claim 40.

157. (New) A method for inhibiting the growth of human breast cancer cells comprising contacting the cells with a compound of claim 41.

158. (New) A method for inhibiting the growth of human breast cancer cells comprising contacting the cells with a compound of claim 116.